Biotech drugs vs. generics, more debate in FDA conference

02/10/2005 | Washington Post, The

The FDA conference next week will assess whether generic drugmakers have the ability to manufacture "follow-on" versions of expensive biologics. Generic drugmakers say the science of biopharmaceuticals has advanced to the point where it is possible to get lower-costing biologics on the market. But brand drugmaker trade associations, including the Biotechnology Industry Organization, argue it is much harder to reverse-engineer a biologic than it is a small molecule drug because of the complications inherent in trying to duplicate complicated and variable proteins that biologics contain.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN